publication date: Jan. 10, 2014


CL40-02c.html

By Conor Hale

Ludwig Cancer Research donated a total of $540 million to six of its centers, located at institutions across the country.

The Ludwig Centers at Harvard University, Johns Hopkins University, the Massachusetts Institute of Technology, Memorial Sloan-Kettering Cancer Center, Stanford University, and the University of Chicago will each receive $90 million for their endowments, which were established along with their respective centers in 2006.

The gift was made on behalf of the organization’s founder, the late Daniel Ludwig, a shipping magnate, and brings the total Ludwig funding for these institutions to $900 million. The new funding was realized by the sale of New York real estate investments held by Ludwig.

“This gift provides a momentous opportunity for the entire Harvard Medical School community to glean new insights into the basic biology of cancer as well as to accelerate the translation of basic research to improve patient outcomes,” said Jeffrey Flier, dean of the faculty of medicine at Harvard, in a statement.

The university plans to expand their center, using the new funds to build upon research activities, attract new biomedical and cancer researchers, and expand collaborations. The expanded center will be co-directed by Joan Brugge, the Louise Foote Pfeiffer Professor of Cell Biology and chair of the HMS Department of Cell Biology, and George Demetri, professor of medicine at HMS and the Quick Family Chair of Medical Oncology at the Dana-Farber Cancer Institute.

At MIT, Ludwig funds currently support its center and six faculty members at the David H. Koch Institute for Integrative … Continue reading 40-02 Ludwig Six

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.